Objectives: We describe for the first time a technology that allows to get a comprehensive overview of the facial arterial anatomy, in augmented reality (AR) on the screen of an iPhone, named ARtery3D. We intended to validate the accuracy of the technology by doppler and duplex and to analyze the effect of ARtery3D on the incidence and duration of bruising.
Introduction: As filler injections are increasingly performed nowadays, there is a rapid rise in the number of complications; intra-arterial injection of HA may lead to skin necrosis or even blindness. Due to a strong variability of the arterial course of the face, one can never guarantee a completely safe filler injection. For the first time, we report a way to visualize the individual arterial anatomy of anyone’s face accurately and dynamically through AR, based on a contrast-free MRA.
Materials / method: - 20 patients who had undergone an MRA were evaluated by doppler and duplex to verify the location of the visualized arteries.
- 200 patients received standardized injections in the malar area, either under visualization of their anatomy using the ARtery3D application, or without. The incidence of bruising was analyzed, size of eventual bruising and duration of the bruises. Injection pain was also measured.
Results: - the average variation of the location of the arteries was 0,3mm (SD +/- 0,7mm), indicating the accuracy of the ARtery3D technology.
- applying the ARtery3D technology yielded a 3-fold decrease in bruising after injections in the malar area, with significantly smaller bruises and shorter duration of the bruises.
Conclusion: Besides reducing the chances on intra-arterial injection, ARtery3D is has become an essential tool to improve the patient comfort and safety in the day-to-day cosmetic practice.
Disclosures
Did you receive any funding to support your research for this TOPIC?
No
Were you provided with any honoraria, payment or other compensation for your work on this study?
No
Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): shareholder
Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
Yes
Please specify date...: approved, pending
and status : Belgian, European
This work was not supported by any direct or non direct funding. It is under the author's own responsability